SIGA Technologies, Inc. (Nasdaq:SIGA) Awarded U.S. Government Contract Valued at Up to $2.8B
- 13 years ago
SIGA Technologies Incorporated is a pharmaceutical company specializing in the development and commercialization of therapeutic solutions for some of the most lethal disease-causing pathogens in the world, including smallpox, Ebola, dengue, Lassa fever and other dangerous viruses—
SIGA Technologies recently reported that it has signed a contract with the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services- HHS- to deliver two million courses of its ST-246 - an oral therapeutic agent active against orthopoxviruses including smallpox - to the Strategic National Stockpile— The 5-year base contract award is worth $433 million and includes options that would raise the contract’s total value to approximately $2.8 billion, if these options are fully exercised— Contract options include the delivery of up to 12 million additional courses of ST-246
SIGA Technologies recently reported that it has signed a contract with the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services- HHS- to deliver two million courses of its ST-246 - an oral therapeutic agent active against orthopoxviruses including smallpox - to the Strategic National Stockpile— The 5-year base contract award is worth $433 million and includes options that would raise the contract’s total value to approximately $2.8 billion, if these options are fully exercised— Contract options include the delivery of up to 12 million additional courses of ST-246